Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site

Article

Abstract: Abiraterone acetate is a first-line therapy for castration-resistant prostate cancer. This prodrug i

Palabras claves:

abiraterone, abiraterone metabolism, CYP17A1, Cytochrome p450, Prostate cancer, steroidogenesis

Autores:

Bart A.G., Peng H.M., Petrunak E.M., Richard J. Auchus, Scott E.E.

Fuentes:

scopus